Unknown

Dataset Information

0

New and future immunomodulatory therapy in type 1 diabetes.


ABSTRACT: Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting ? cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.

SUBMITTER: Tooley JE 

PROVIDER: S-EPMC3586241 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

New and future immunomodulatory therapy in type 1 diabetes.

Tooley James E JE   Waldron-Lynch Frank F   Herold Kevan C KC  

Trends in molecular medicine 20120217 3


Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogen  ...[more]

Similar Datasets

| S-EPMC3189545 | biostudies-literature
| S-EPMC5552844 | biostudies-literature
| S-EPMC1274281 | biostudies-literature
| S-EPMC8012324 | biostudies-literature
| S-EPMC10721089 | biostudies-literature
| S-EPMC7116807 | biostudies-literature
| S-EPMC6305869 | biostudies-other
| S-EPMC5012675 | biostudies-literature
| S-EPMC9370092 | biostudies-literature
| S-EPMC3673829 | biostudies-other